Kondo H, Mori H, Ito K, Siraki S, Tamaya T, Yamada Y, Noda K
Nihon Gan Chiryo Gakkai Shi. 1989 Aug 20;24(8):1600-6.
Clinical study was performed to review the treatment of carcinoma of the uterine cervix in 525 cases treated by surgery, radiotherapy, the combination of both, and others at Dept. of Obstetrics and Gynecology, Gifu University Hospital during 10 years from April 1, 1972 through March 31, 1982. 1) Of 525 cases, 80 were classified as stage 0 by the criteria of FIGO, 178 as stage I (39 as Ia, 139 as Ib), 164 as stage II(8 as IIa, 156 as IIb), 98 as stage III and 5 as stage IV. 2) The five year cumulative survival rate was 78.2% for all invasive 445 cases excluding stage 0, 93.8% for stage I, 82.3% for stage II, 45.9% for stage III, and 20.0% for stage IV. 3) The five year cumulative survival rate was 85.1% for stage II cases which were treated by surgery or the combination of surgery and radiotherapy, and 63.8% for stage III. However the five year cumulative survival rate was 60.0% for stage II cases which were treated by radiotherapy only, and 32.0% for stage III. 4) The rate for the cases with adenocarcinoma was 3.8% (17/445) in all invasive carcinoma of the uterine cervix. The five year cumulative rate was 47.1% for the cases with adenocarcinoma, and 79.4% for those with squamous cell carcinoma.
对岐阜大学医院妇产科1972年4月1日至1982年3月31日10年间收治的525例子宫颈癌患者进行了临床研究，这些患者接受了手术、放疗、手术联合放疗及其他治疗。1）525例患者中，按照国际妇产科联盟（FIGO）标准，80例为0期，178例为I期（Ia期39例，Ib期139例），164例为II期（IIa期8例，IIb期156例），98例为III期，5例为IV期。2）除0期外的445例浸润性癌患者的5年累积生存率为78.2%，I期为93.8%，II期为82.3%，III期为45.9%，IV期为20.0%。3）接受手术或手术联合放疗的II期患者5年累积生存率为85.1%，III期为63.8%。然而，单纯接受放疗的II期患者5年累积生存率为60.0%，III期为32.0%。4）在所有子宫颈浸润性癌中，腺癌患者的比例为3.8%（17/445）。腺癌患者的5年累积生存率为47.1%，鳞状细胞癌患者为79.4%。
